Study Details
Full Title
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC), the SYNERGY-201 Trial
Principal Investigator
Andrew
Armstrong
Protocol Number
PRO00113209
NCT ID
NCT06228053
Phase
II
Enrollment Status
Open to Enrollment